Detail akcie BioNTech Sp ADS online

Business Summary: BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, BioNTech SE - ADR revenues decreased 33% to EUR1.56B. Net loss totaled EUR924.8M vs. income of EUR472.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Gain on derivative instruments at fair v decrease of 92% to EUR5.7M (income), Loss on derivative instruments at fair v increase from EUR0K to EUR31.9M (expense).